1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373(6510):123-6. doi: 10.1038/373123a0.
2. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science. 1998;282(5386):103-7.
3. Nowak M, May RM. Virus dynamics: mathematical principles of immunology and virology: mathematical principles of immunology and virology: Oxford University Press, UK; 2000.
4. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271(5255):1582-6. doi: 10.1126/science.271.5255.1582.
5. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV1-infected compartments during combination therapy. Nature. 1997;387(6629):188-91.
6. Perelson AS. Modelling viral and immune system dynamics. Nat Rev ImmunolNature Reviews Immunology. 2002;2(1):28-36. doi: 10.1038/nri700.
7. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nature medicine. 2012;18(3):446-51.
8. Koizumi Y, Ohashi H, Nakajima S, Tanaka Y, Wakita T, Perelson AS, et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proceedings of the National Academy of Sciences. 2017;114(8):1922-7.
9. Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, et al. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-ofconcept study. The Lancet Gastroenterology & Hepatology. 2016;1(2):97-104.
10. Ohashi H, Koizumi Y, Fukano K, Wakita T, Perelson AS, Iwami S, et al. Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments. Proceedings of the National Academy of Sciences. 2017;114(23):E4527-E9.
11. Cheng R, Tu T, Shackel N, McCaughan GW. Advances in and the future of treatments for hepatitis C. Expert review of gastroenterology & hepatology. 2014;8(6):633-47.
12. Pawlotsky J-M. Hepatitis C treatment: the data flood goes on—an update from the liver meeting 2014. Gastroenterology. 2015;148(3):468-79.
13. Best K, Guedj J, Madelain V, de Lamballerie X, Lim S-Y, Osuna CE, et al. Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies. Proceedings of the National Academy of Sciences. 2017;114(33):8847-52.
14. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus halflife. Proceedings of the National Academy of Sciences. 2013;110(10):3991-6.
15. Guedj J, Neumann A. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. Journal of theoretical biology. 2010;267(3):330-40.
16. Rong L, Guedj J, Dahari H, Coffield Jr DJ, Levi M, Smith P, et al. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol. 2013;9(3):e1002959.
17. Rong L, Perelson AS. Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. Math Biosci. 2013;245(1):22-30. doi: 10.1016/j.mbs.2013.04.012.
18. Auger P, Charles S, Viala M, Poggiale J-C. Aggregation and emergence in ecological modelling: integration of ecological levels. Ecological Modelling. 2000;127(1):11-20.
19. Iwasa Y, Andreasen V, Levin S. Aggregation in model ecosystems. I. Perfect aggregation. Ecol ModellEcological Modelling. 1987;37(3-4):287-302. doi: 10.1016/0304-3800(87)90030-5.
20. Iwasa Y, Levin SA, Andreasen V. Aggregation in model ecosystems II. Approximate aggregation. Mathematical Medicine and Biology: A Journal of the IMA. 1989;6(1):1-23.
21. Martyushev A, Nakaoka S, Sato K, Noda T, Iwami S. Modelling Ebola virus dynamics: implications for therapy. Antivir ResAntiviral research. 2016;135:62-73. doi: 10.1016/j.antiviral.2016.10.004.
22. Inaba H. Age-structured population dynamics in demography and epidemiology: Springer; 2017.
23. Ozaras R, Yemisen M, Balkan İİ. Current and future therapies for hepatitis C virus infection. The New England journal of medicine. 2013;369(7).
24. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64(11):1824-33.
25. Hecht F. New development in freefem+. Journal of Numerical Mathematics. 2012;20(3-4):251-65. doi: 10.1515/jnum-2012-0013.
26. Gelman A, Lee D, Guo J. Stan: A probabilistic programming language for Bayesian inference and optimization. Journal of Educational and Behavioral Statistics. 2015;40(5):530-43.
27. Team RC. R: A language and environment for statistical computing [Computer software manual]. Vienna, Austria. 2016.
28. Tornøe CW, Agersø H, Jonsson EN, Madsen H, Nielsen HA. Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations. Computer Methods and Programs in Biomedicine. 2004;76(1):31-40. doi: https://doi.org/10.1016/j.cmpb.2004.01.001.
29. Dietz J, Susser S, Vermehren J, Peiffer K-H, Grammatikos G, Berger A, et al. Patterns of resistanceassociated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology. 2018;154(4):976-88. e4.
30. Iwami S, Sato K, De Boer RJ, Aihara K, Miura T, Koyanagi Y. Identifying viral parameters from in vitro cell cultures. Frontiers in microbiology. 2012;3:319.
31. Beauchemin CA, Miura T, Iwami S. Duration of SHIV production by infected cells is not exponentially distributed: Implications for estimates of infection parameters and antiviral efficacy. Scientific reports. 2017;7:42765.
32. Ikeda H, Godinho-Santos A, Rato S, Vanwalscappel B, Clavel F, Aihara K, et al. Quantifying the antiviral effect of IFN on HIV-1 replication in cell culture. Scientific reports. 2015;5(1):1-8.
33. Iwami S, Holder BP, Beauchemin CA, Morita S, Tada T, Sato K, et al. Quantification system for the viral dynamics of a highly pathogenic simian/human immunodeficiency virus based on an in vitroexperiment and a mathematical model. Retrovirology. 2012;9(1):18.
34. Iwami S, Takeuchi JS, Nakaoka S, Mammano F, Clavel F, Inaba H, et al. Cell-to-cell infection by HIV contributes over half of virus infection. Elife. 2015;4:e08150.
35. Iwanami S, Kakizoe Y, Morita S, Miura T, Nakaoka S, Iwami S. A highly pathogenic simian/human immunodeficiency virus effectively produces infectious virions compared with a less pathogenic virus in cell culture. Theoretical Biology and Medical Modelling. 2017;14(1):9.
36. Kakizoe Y, Morita S, Nakaoka S, Takeuchi Y, Sato K, Miura T, et al. A conservation law for virus infection kinetics in vitro. Journal of Theoretical Biology. 2015;376:39-47.
37. Kakizoe Y, Nakaoka S, Beauchemin CA, Morita S, Mori H, Igarashi T, et al. A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic SHIV strain. Scientific reports. 2015;5(1):1-14.
38. Iwami S, Takeuchi Y, Liu X. Avian-human influenza epidemic model. Math Biosci. 2007;207. doi: 10.1016/j.mbs.2006.08.001.
39. Iwami S, Takeuchi Y, Liu X, Nakaoka S. A geographical spread of vaccine-resistance in avian influenza epidemics. J Theor Biol. 2009;259. doi: 10.1016/j.jtbi.2009.03.040.
40. McCluskey CC. Global stability for an SEI epidemiological model with continuous age-structure in the exposed and infectious classes. Math Biosci Eng MBE. 2012;9. doi: 10.3934/mbe.2012.9.819.
41. Melnik AV, Korobeinikov A. Lyapunov functions and global stability for SIR and SEIR models with age-dependent susceptibility. Math Biosci Eng MBE. 2013;10. doi: 10.3934/mbe.2013.10.369.
42. Rong L, Feng Z, Perelson AS. Mathematical analysis of age-structured HIV-1 dynamics with combination antiretroviral therapy. SIAM J Appl Math. 2007;67. doi: 10.1137/060663945.
43. Huang G, Liu X, Takeuchi Y. Lyapunov functions and global stability for age-structured HIV infection model. SIAM J Appl Math. 2012;72. doi: 10.1137/110826588.
44. Wang J, Zhang R, Kuniya T. Global dynamics for a class of age-infection HIV models with nonlinear infection rate. J Math Anal Appl. 2015;432. doi: 10.1016/j.jmaa.2015.06.040.
45. Perelson AS, Nelson PW. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 1999;41. doi: 10.1137/S0036144598335107.
46. Althaus CL, Vos AS, Boer RJ. Reassessing the human immunodeficiency virus type 1 life cycle through age-structured modeling: life span of infected cells, viral generation time, and basic reproductive number, R0. J Virol. 2009;83. doi: 10.1128/JVI.01799-08.
47. Nelson PW, Gilchrist MA, Coombs D, Hyman JM, Perelson AS. An age-structured model of HIV infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells. Math Biosci Eng MBE. 2004;1. doi: 10.3934/mbe.2004.1.267.
48. Quintela BM, Conway JM, Hyman JM, Guedj J, Santos RW, Lobosco M, et al. A new age-structured multiscale model of the Hepatitis C virus life-cycle during infection and therapy with direct-acting antiviral agents. Front Microbiol. 2018;9. doi: 10.3389/fmicb.2018.00601.
49. Reinharz V, Dahari H, Barash D. Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics. Math Biosci. 2018;300. doi: 10.1016/j.mbs.2018.03.011.
50. Kitagawa K, Nakaoka S, Asai Y, Watashi K, Iwami S. A PDE multiscale model of hepatitis C virus infection can be transformed to a system of ODEs. J Theor Biol. 2018;448. doi: 10.1016/j.jtbi.2018.04.006.
51. Peifer M, Timmer J. Parameter estimation in ordinary differential equations for biochemical processes using the method of multiple shooting. IET Syst Biol. 2007;1. doi: 10.1049/iet-syb:20060067.
52. Frohlich F, Kaltenbacher B, Theis FJ, Hasenauer J. Scalable parameter estimation for genome-scale biochemical reaction networks. PLoS Comput Biol. 2017;13. doi: 10.1371/journal.pcbi.1005331.
53. Inaba H. On a new perspective of the basic reproduction number in heterogeneous environments. J Math Biol. 2012;65. doi: 10.1007/s00285-011-0463-z.
54. Wei X. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373. doi:10.1038/373117a0.
55. Ramratnam B. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 1999;354. doi: 10.1016/S0140-6736(99)02035-8.
56. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432. doi: 10.1038/nature03153.
57. Pinilla LT, Holder BP, Abed Y, Boivin G, Beauchemin CA. The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets. J Virol. 2012;86. doi: 10.1128/JVI.07244-11.
58. Magal P, McCluskey C, Webb G. Lyapunov functional and global asymptotic stability for an infectionage model. Appl Anal. 2010;89. doi: 10.1080/00036810903208122.
論文の公開元へ
